Your browser is no longer supported. Please, upgrade your browser.
AUTL Autolus Therapeutics plc daily Stock Chart
Autolus Therapeutics plc
Index- P/E- EPS (ttm)-1.42 Insider Own3.52% Shs Outstand40.15M Perf Week-8.52%
Market Cap1.25B Forward P/E- EPS next Y-2.11 Insider Trans- Shs Float32.23M Perf Month2.44%
Income- PEG- EPS next Q- Inst Own47.13% Short Float2.34% Perf Quarter10.43%
Sales1.41M P/S885.38 EPS this Y- Inst Trans- Short Ratio9.20 Perf Half Y32.83%
Book/sh6.36 P/B4.88 EPS next Y15.60% ROA- Target Price45.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range19.17 - 53.24 Perf YTD-5.51%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.72% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low61.84% ATR2.87
Employees166 Current Ratio- Sales Q/Q-7.60% Oper. Margin- RSI (14)44.30 Volatility6.35% 9.16%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.93 Prev Close31.40
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume82.05K Price31.03
Recom- SMA20-3.06% SMA50-11.70% SMA2003.15% Volume158,661 Change-1.18%
Oct-24-18Initiated H.C. Wainwright Buy $45
Jan-16-19 09:05AM  Alexandria Fully Leases New Built-to-Suit Facility to Autolus Zacks
Jan-14-19 08:28AM  Biotech to create 170 jobs, invest $28M in new Rockville HQ American City Business Journals -5.51%
07:55AM  Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters PR Newswire
Jan-09-19 07:02PM  MoCo economic development officials plan satellite office in Boston American City Business Journals
12:20PM  London biotech firm planning new U.S. HQ, research facility in Rockville American City Business Journals
Dec-20-18 04:32PM  Autolus Therapeutics to Join NASDAQ Biotechnology Index PR Newswire
Dec-03-18 03:27AM  Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes PR Newswire +5.54%
03:25AM  Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH PR Newswire
Dec-02-18 11:01AM  Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting PR Newswire
Dec-01-18 09:16PM  Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL) PR Newswire
Nov-23-18 08:30AM  Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F PR Newswire
Nov-02-18 07:42AM  Autolus Therapeutics to Present New Data at the ASH Annual Meeting PR Newswire
Nov-01-18 09:10AM  Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting PR Newswire +10.53%
Oct-30-18 08:30AM  Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference PR Newswire
Oct-17-18 08:30AM  Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality PR Newswire
Sep-27-18 08:20PM  UK biotech raises bumper $2 billion, despite Brexit blues Reuters +7.12%
Aug-30-18 08:33AM  Autolus to Present at Upcoming Investor Conferences PR Newswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
07:07PM  [$$] Autolus, ElectroCore IPOs Cap Strong Week for Life Sciences The Wall Street Journal
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.